Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
Open Access
- 10 December 2019
- journal article
- research article
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 19 (1) , 1-13
Abstract
Background: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. Methods: A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. Results: Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. Conclusion: By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking.Keywords
Funding Information
- National Science Foundation of China (81873037)
- Instituto Nacional de Ciência e Tecnologia da Criosfera (2018YFC1704500)
This publication has 38 references indexed in Scilit:
- Acute desensitization of acetylcholine and endothelin-1 activated inward rectifier K+ current in myocytes from the cardiac atrioventricular nodeBiochemical and Biophysical Research Communications, 2012
- Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional studyBMC Medical Research Methodology, 2011
- TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In SilicoPLOS ONE, 2011
- Oxytocin protects rat heart against ischemia–reperfusion injury via pathway involving mitochondrial ATP-dependent potassium channelPeptides, 2010
- AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic diseaseClinical Science, 2009
- TCMGeneDIT: a database for associated traditional Chinese medicine, gene and disease information using text miningBMC Complementary and Alternative Medicine, 2008
- Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validationBritish Journal of Pharmacology, 2006
- What Is the Role of β-Adrenergic Signaling in Heart Failure?Circulation Research, 2003
- The Evaluation and Management of BradycardiaNew England Journal of Medicine, 2000
- Assessing the quality of randomized controlled trials: An annotated bibliography of scales and checklistsControlled Clinical Trials, 1995